AzTrials
AzTrials

Mammogram UptakeREMIND1NCT07651345

Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore

A study testing Arm 2: One mailed reminder, Arm 3: Two mailed reminders and Arm 4: Mailed reminder with prescheduled appointment in people with Mammogram Uptake and Breast Cancer, run by National University Hospital, Singapore at 1 site in Singapore.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record

Search all trials

Trial summary

Breast cancer is the most common cancer among women in Singapore, accounting for nearly 30% of all female cancers. While regular biennial mammography can reduce mortality, screening rates in Singapore remain low at 34.7%; well below the 70% threshold required for population-level impact. Read more about this study

Who is it for?
Ages 50 to 69 years, women onlyHealthy volunteers can take part
Conditions the study is for
Mammogram Uptake, Breast Cancer, Breast Neoplasm
What is being tested?
Arm 2: One mailed reminder, Arm 3: Two mailed reminders and Arm 4: Mailed reminder with prescheduled appointment
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12,750 participants
Where
1 siteSingapore
Study dates
9 Mar 2026to 31 Dec 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 69 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Singaporean citizen
  • Age 50-69
  • Registered as a patient at the National University Hospital
  • Registered and active user of NUHS App
  • Signed up with Healthier SG with a primary care provider within the NUHS Primary Care Network
  • Must be defaulted repeat screeners : Must have done one prior mammogram screening but not in the past 2 years

Who cannot join

  • Diagnosis of breast cancer in EPIC
  • Mammogram done in the past 24 months in EPIC

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Singapore1 site
  • National University Hospital Singapore

    Singapore

Other trials in Singapore

About this study

Official title: Randomized Controlled Trials to Evaluate Outreach Strategies for Increasing Mammogram Uptake in Singaporean Women Who Are Defaulted Repeat Screeners

Breast cancer is the most common cancer among women in Singapore, accounting for nearly 30% of all female cancers. While regular biennial mammography can reduce mortality, screening rates in Singapore remain low at 34.7%; well below the 70% threshold required for population-level impact. Despite a national screening program in place since 2002, uptake continues to be hindered by psychological, cultural, and logistical barriers. Although various studies have explored different behavioural interventions to boost mammogram uptake; ranging from reminders (traditional mailers, phone calls, text messages) and education to financial incentives, their effectiveness varies by population and context. Furthermore, few large-scale, prospective studies have been conducted locally. Prior research in Singapore is either outdated or limited in scope, and there is a particular lack of rigorous trials evaluating behavioral interventions tailored to women who have defaulted on screening, who faces distinct psychological and behavioral barriers; ranging from low perceived risk and fear, to false reassurance from prior normal results or lack of reminders, or had bad experience (procedural pain or prior false positive results) during last mammogram. Engaging these women is critical, yet challenging, and failure to do so undermines efforts to achieve broad population coverage.

The REMIND Study addresses this critical gap by evaluating five pragmatic and scalable outreach strategies to increase mammogram uptake among women who had their last screening more than 2 years ago and are currently overdue. Through a large, randomized controlled trial, the study will generate much-needed local evidence on what works to reengage these women. Findings will directly inform national screening policies and the design of future outreach efforts tailored to Singapore's diverse population.

Read the detailed description

The REMIND Study is a five-arm randomized controlled trial (RCT) designed to evaluate the effectiveness of a few behavioral interventions to increase mammogram uptake among women aged 50-69 years who have defaulted on mammogram screening. The study's specific aim is to identify effective, affordable, and scalable behavioral interventions that can be implemented in Singapore's general population to improve participation in surveillance mammography. This is a minimal-risk, population-based study that does not require participant visits or in-person interaction, except for a subset involved in a follow-up telephone survey.

Eligibility Criteria: Singaporean women, aged 50-69, who are eligible for free biennial mammograms, with no history of prior breast cancer, have had at least one mammogram before, but not screened in the past 2 years will be will be identified using the NUH electronic medical health records system (EPIC). We will restrict the selection to NUHS patients who are registered users of the NUHS App. To further select/narrow down the eligible participants app activity or last log in date will be used. Patients who signed up the NUHS App have all consented to receive push notifications on research studies. There are over 600,000 registered users of NUHS App. The required 12,750 patients for the study will be randomly selected from these eligible patients.

Randomization and Intervention Arms: A total of 12,750 eligible women will be randomly assigned in equal proportions (n=2,550 per arm) to one of the following five groups:

  1. no intervention (control);
  2. standard mailed reminder (MR);
  3. MR plus a second MR sent four weeks later;
  4. MR with a pre-scheduled mammogram appointment; and
  5. MR containing behavioral nudge messaging (e.g., social norm or gain or loss framing techniques).

Randomization will be computer-generated. NOTE: Arm 1 represents the current standard practice at NUHS, where patients are not routinely invited or reminded to attend mammogram screenings.

Women in intervention arms 2-5 will receive their respective outreach materials by post (personalized mailers on NCIS letter head) as well as push notifications via the NUHS app. 5-7 days after the mailers are sent, 1st batch of PN will be sent. Up to three batches of PN will be sent to all participants in Arms 2-5, 3 weeks apart. The push notifications will either be linked to a microcontent landing page or a webpage on NCIS website. The content of the mailers and landing page/ webpage will be the same explaining the importance of regular mammography, tailored messages according to each intervention type, and relevant booking instructions or appointment details. These materials have been designed to reflect evidence-based behavioral science strategies and were co-developed in consultation with clinicians, behavioural science experts, and community stakeholders. Participants in the control arm (Arm 1) will not receive any intervention.

This is a minimal-risk study. There are no in-person visits, clinical procedures, or additional tests required. Participation primarily involves receiving reminders. Women may choose to opt out of the study at any time.

Outcome measurement: All data on mammogram completion will be obtained from existing sources such as electronic medical records and the national screening registry. The primary outcome is mammogram uptake within four months of the first intervention (date of sending the mailer/ push notification, which ever is later). In addition to the primary time point, mammogram uptake data may also be extracted at the 6-month and 12-month marks following the intervention. These extended follow-up points will allow for the assessment of any delayed uptake, which may help to understand the longer-term impact of the interventions. No new clinical data will be generated from participants.

NOTE: To avoid a huge surge in calls to the appointment booking hotline number, mailers will be sent in a staggered manner over 4-12 weeks. Hence, the collection of mammogram completion data will also be staggered and will be 4 months from the day of sending the mailers/PNs which ever is the later. Similarly, for the participants in Arm 4 (mailer reminder with pre-scheduled appointment), the mailers/PN will be sent out 4-6 weeks prior to the appointment date and the mammogram completion date will be calculated four months from the date the mailer/PN was sent.

Post-trial telephone survey: In addition post-trial, a subset of participants from Arms 2-5, will be randomly selected to participate in a telephone survey aimed at understanding motivations, barriers, and perceptions related to the interventions and screening. Participants will be randomly selected and contacted until a total of up to 70 participants in each arm responds and takes part in the survey. About 3-8 weeks post trial, the participants will be contacted via phone, and verbal consent will be obtained prior to initiating the survey. They will be informed that the survey will take about 5-10 minutes, their participation is voluntary, they may skip any question or withdraw at any time, and their responses will remain confidential. Trained research staff will be performing the telephone survey.

Being tested
Arm 2: One mailed reminder, Arm 3: Two mailed reminders, Arm 4: Mailed reminder with prescheduled appointment, Arm 5: Mailed reminder
Keywords
Mammography, Behavioural Intervention, Breast cancer detection, early detection, Mailed reminder, Cancer Screening, Breast cancer
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Arm 2: One mailed reminderBehavioural

    Receives a mailed reminder with basic information about breast cancer and instructions on scheduling a mammogram

  • Arm 3: Two mailed remindersBehavioural

    Receives a mailed reminder + follow-up mailed reminder, 4 weeks after the first

  • Arm 4: Mailed reminder with prescheduled appointmentBehavioural

    Receives one mailed reminder with a pre-scheduled appointment, with instructions to change appointment

  • Arm 5: Mailed reminderBehavioural

    Receives one mailed reminder with enhanced messaging motivating recipient to undergo screening

Study groups in NCT07651345
Study groupRoleWhat they receive
Control Arm (Arm 1)No interventionDoes not receive any reminder to go for mammogram
Arm 2: One mailed reminderExperimentalReceives a single mail reminder
Receives: Behavioral: Arm 2: One mailed reminder
Arm 3: Two mailed remindersExperimentalReceives two mail reminders, 4 weeks apart
Receives: Behavioral: Arm 3: Two mailed reminders
Arm 4: Mailed Reminder with Prescheduled AppointmentExperimentalReceives a mailed reminder with prescheduled appointment
Receives: Behavioral: Arm 4: Mailed reminder with prescheduled appointment
Arm 5: Mailed reminder with enhanced messagingExperimentalReceives mailed reminder with enhanced messaging
Receives: Behavioral: Arm 5: Mailed reminder

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of proportion of participants completing surveillance mammography within 4 months after intervention assignment between interventional arms (2-5) and control arm (Arm 1)

    The proportion of women who undergo surveillance mammography within 4 months of receiving the study intervention/reminder will be compared between Arm 1 (control) and Arms 2-5. Mammogram completion will be confirmed through electronic medical records. Results will be reported as the percentage of participants completing mammography in each study arm. Unit of Measure: Percentage of participants (%)

    Measured: 4 months from the time participants receive the intervention/reminder

Secondary outcomes (3)
  1. Association between participant characteristics and completion of surveillance mammography within 4 months

    Multivariable logistic regression will be used to evaluate the association between participant characteristics and mammogram completion within 4 months after intervention. Covariates include age, race, housing type, and duration overdue for screening. Results will be reported as adjusted odds ratios with 95% confidence intervals.

    Measured: 4 months from the time participants receive the intervention/reminder

  2. Post-trial telephone survey

    A post-trial telephone survey of about 280 participants will gather insights into their response to the interventions. The study aims to provide actionable insights into effective, scalable interventions to improve mammography uptake and reduce breast cancer mortality in Singapore.

    Measured: 1-2 months post-trial

  3. Mammogram uptake at 6 and 12 months post-trial

    Comparison of mammogram completion 6 and 12 months after the initial study

    Measured: 6 and 12 months from the time participants received the first mailed reminder

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jun 2026
  2. Study start9 Mar 2026
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
12,750 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07651345
Sponsor's protocol ID
2025-0790
Acronym
REMIND1
Status last verified
Apr 2026
First submitted
21 May 2026
Last updated
16 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in